Idenix Pharmaceuticals (IDIX)

[go seek]

Preclinical data for IDX899 and IDX989 demonstrated activity against a broad panel of wild-type HIV-1 isolates Co announces that preclinical data from two novel non-nucleoside reverse transcriptase inhibitors for the treatment of human immunodeficiency virus type 1 infection, IDX899 and IDX989, demonstrated potent and selective activity in vitro. These data were presented today by Dr. Douglas Richman at the 14th Conference on Retroviruses and Opportunistic Infections. Preclinical data for IDX899 and IDX989 demonstrated activity against a broad panel of wild-type HIV-1 isolates. Potency was retained against panels of clinical isolates containing various single and double NNRTI mutations. Both compounds exhibited good oral bioavailability with a favorable pharmacokinetic profile. A favorable toxicology profile was also reported as genotoxicity studies were negative and no major adverse effects were observed in acute toxicity studies. IDX899 and IDX989 showed inhibition of CYP450 3A4, 2C8 and 2C9. Preliminary clinical evaluation of both Idenix compounds has been conducted under an exploratory Investigational New Drug application. A lead candidate, IDX899, has been selected for further clinical development based on its overall profile and IDX989 will remain a back-up candidate.

http://news.moneycentral.msn.com/ticker/article.aspx?Feed=Bcom&Date=20070301&ID=6559137&....